First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
DLBCL · High-grade B-cell Lymphoma (HGBCL) · Primary Mediastinal Large B-cell Lymphoma (PMBCL) · FL · MCL · Small Lymphocytic Lymphoma (SLL) · Marginal Zone Lymphoma (MZL) · Indolent B-cell Non-Hodgkin Lymphoma (iNHL) · Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 666 (final count)
- Started
- Jun 26, 2018
- Main results expected
- Jan 2029
- Fully finished
- Jan 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose-Escalation: Dose Limiting Toxicity (DLT)
Measured over: During the first cycle (28 days)
Dose-Escalation: Number of Participants with Adverse Events (AEs)
Measured over: From first dose until the end of the safety follow-up period (Up to 1 year)
Expansion: Overall Response Rate (ORR)
Measured over: Up to 1.5 years
Dose-OPT DLBCL, FL and MCL: Percentage of Participants with =>Grade 2 Cytokine Release Syndrome (CRS) Events and All Grade CRS Events
Measured over: From first dose until 7 days after second full dose (Day 28 for DLBCL; Day 35 for FL; Day 28-35 for MCL)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03625037 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC